Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. (linkinghub.elsevier.com)

Authors: Rosenstock J … Jain AB Journal: The Lancet Published: 2026-06-07 DOI: https://doi.org/10.1016/S0140-6736(26)01022-6